Milan, August 5, 2015 - Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the Canadian approval of its Perceval sutureless aortic valve.

Traditional valves require from 15 to 18 permanent sutures, but the Perceval valve is designed with a unique self-anchoring frame that enables the surgeon to replace the native diseased valve without sutures.

click here to view the release

distributed by